DNA synthesis inhibitors: Metronidazole

20,737views

DNA synthesis inhibitors: Metronidazole

NP Pharm

NP Pharm

Introduction to pharmacology
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Drug administration and dosing regimens
Non-steroidal anti-inflammatory drugs
Acetaminophen (Paracetamol)
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid antagonists
Glucocorticoids
Osteoporosis medications
Antigout medications
General anesthetics
Local anesthetics
Neuromuscular blockers
Medications for neurodegenerative diseases
Anti-parkinson medications
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Adrenergic antagonists: Beta blockers
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Positive inotropic medications
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Antihistamines for allergies
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Potassium sparing diuretics
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Miscellaneous hypoglycemics
Hypoglycemics: Insulin secretagogues
Non-corticosteroid immunosuppressants and immunotherapies
Methemoglobinemia
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Anti-tumor antibiotics
Antimetabolites for cancer treatment
Monoclonal antibodies
DNA alkylating medications
PDE5 inhibitors
Androgens and antiandrogens
Adrenergic antagonists: Alpha blockers
Estrogens and antiestrogens
Progestins and antiprogestins
Aromatase inhibitors
Uterine stimulants and relaxants
Acid reducing medications
Laxatives and cathartics
Antidiarrheals
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Atypical antidepressants
Tricyclic antidepressants
Monoamine oxidase inhibitors
Typical antipsychotics
Atypical antipsychotics
Nonbenzodiazepine anticonvulsants
Lithium
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Psychomotor stimulants
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Protein synthesis inhibitors: Tetracyclines
Protein synthesis inhibitors: Aminoglycosides
Miscellaneous protein synthesis inhibitors
Antituberculosis medications
Antimetabolites: Sulfonamides and trimethoprim
Mechanisms of antibiotic resistance
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Hepatitis medications
Herpesvirus medications
Azoles
Miscellaneous antifungal medications
Anthelmintic medications
Anti-mite and louse medications
Antimalarials

Transcript

Watch video only

DNA synthesis inhibitors are a group of antibiotics that target the synthesis of DNA in bacteria and other organisms. Metronidazole, a 5-nitroimidazole, prevents the synthesis of nucleic acids, which are the building blocks of DNA, and is effective against many bacteria and protozoans.

Metronidazole and related 5-nitroimidazoles are relatively nontoxic to humans. This is because in order to function, they need to be reduced by a protein called ferredoxin, which contains sulfur and iron. This protein is commonly found in anaerobic bacteria and protozoans, but is not as available in humans and aerobic bacteria. Now, this protein can donate an electron to metronidazole, causing it to form free radicals which will damage the DNA, causing it to fragment. Without the DNA as a template, the organism can’t synthesize any more nucleic acids like DNA or mRNA, which will lead to cell death.

Metronidazole can be taken orally, but it’s also available in an IV form and as topical creams. It penetrates well into body tissues and fluids, including vaginal secretions, seminal fluid, saliva, breast milk, cerebrospinal fluid, and crosses over the placenta.

This medication can treat many anaerobic bacterial infections like Clostridioides difficile, which can cause pseudomembranous enterocolitis in people taking other antibiotics. Another common organism treated by this medication is Helicobacter pylori, a common bacteria that causes gastritis and peptic ulcers. However, it should be used in combination with other antimicrobials and proton pump inhibitors as part of a triple therapy for the best outcome when treating this condition. Next, Gardnerella vaginalis and other anaerobes that can cause bacterial vaginosis are all treated by metronidazole.

For protozoan infections, it’s the medication of choice for amoebiasis, an infection of the gut caused by Entamoeba histolytica. It’s the medication of choice against Trichomonas vaginalis as well, which causes vaginal trichomoniasis. Finally, metronidazole is highly effective against giardiasis, or beaver fever, which is an infection of the gut caused by Giardia lamblia.

Metronidazole is metabolized in the liver and it’s an inhibitor of CYP450 enzymes, so it can slow down the metabolism of other medications, like warfarin, which are also broken down by this enzyme.

Common side effects of metronidazole include decreased appetite, nausea, a metallic taste in the mouth, headaches, and stomach cramps.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review, 12th ed. © (ISBN-13: 978-1259641022) " Katzung (2018 )
  2. "Rang & Dale’s Pharmacology, 9th ed,. © (ISBN-13: 978-0702074486) " Ritter (2019 )
  3. "Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th ed. (ISBN-13: 978-1259584732 " Brunton
  4. "Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). 66(7), e1-e48. " Clinical Infectious Diseases (2018)
  5. "Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy. 28(s1), S57-S65. " Clinical Infectious Diseases (1999)
  6. "Sudden Death Due to Metronidazole/Ethanol Interaction. 17(4), 343-346." The American Journal of Forensic Medicine and Pathology (1996)
  7. "A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease Severity. 45(3), 302-307. " Clinical Infectious Diseases (2007)
  8. "Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action. Journal of Antimicrobial 31(1), 9-20. " Chemotherapy (1993)